Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01371981 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1645

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia
Leukemia Cutis
Myeloid Neoplasm
Myeloid Sarcoma

Interventions

DRUG: Asparaginase
DRUG: Bortezomib
DRUG: Cytarabine
DRUG: Daunorubicin Hydrochloride
DRUG: Etoposide
OTHER: Laboratory Biomarker Analysis
DRUG: Mitoxantrone Hydrochloride
OTHER: Pharmacological Study
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)